Chapter 22

Drug-Eluting Coronary Stents

Hesha J. Duggirala PhD, MPH

Hesha J. Duggirala PhD, MPH

Epidemiologist

Epidemiology Branch, Division of Postmarket Surveillance, Office of Surveillance and Biometrics, Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Drive, HFZ-541, Rockville, MD 20850, USA

Search for more papers by this author
Thomas P. Gross MD, MPH

Thomas P. Gross MD, MPH

Director

Division of Postmarket Surveillance, Office of Surveillance and Biometrics, Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Drive, HFZ-520, Rockville, MD 20850, USA

Search for more papers by this author
David E. Kandzari MD

David E. Kandzari MD

Assistant Professor of Medicine

Department of Medicine, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA

Search for more papers by this author
First published: 02 March 2007

Summary

This chapter contains sections titled:

  • History and evolution of coronary stents: clinical perspective

  • Novel drug-eluting stent programs

  • Comparative trials of drug-eluting stents

  • Application of drug-eluting stents in complex coronary lesion subsets

  • Drug-eluting stents: regulatory perspective

  • References

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.